Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama Heersink School of Medicine, Birmingham.
Pulmonary Section, Birmingham Veteran's Affairs Medical Center, Birmingham, Alabama.
JAMA. 2022 Jul 19;328(3):270-279. doi: 10.1001/jama.2022.9792.
Hypotension is common during tracheal intubation of critically ill adults and increases the risk of cardiac arrest and death. Whether administering an intravenous fluid bolus to critically ill adults undergoing tracheal intubation prevents severe hypotension, cardiac arrest, or death remains uncertain.
To determine the effect of fluid bolus administration on the incidence of severe hypotension, cardiac arrest, and death.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled 1067 critically ill adults undergoing tracheal intubation with sedation and positive pressure ventilation at 11 intensive care units in the US between February 1, 2019, and May 24, 2021. The date of final follow-up was June 21, 2021.
Patients were randomly assigned to receive either a 500-mL intravenous fluid bolus (n = 538) or no fluid bolus (n = 527).
The primary outcome was cardiovascular collapse (defined as new or increased receipt of vasopressors or a systolic blood pressure <65 mm Hg between induction of anesthesia and 2 minutes after tracheal intubation, or cardiac arrest or death between induction of anesthesia and 1 hour after tracheal intubation). The secondary outcome was the incidence of death prior to day 28, which was censored at hospital discharge.
Among 1067 patients randomized, 1065 (99.8%) completed the trial and were included in the primary analysis (median age, 62 years [IQR, 51-70 years]; 42.1% were women). Cardiovascular collapse occurred in 113 patients (21.0%) in the fluid bolus group and in 96 patients (18.2%) in the no fluid bolus group (absolute difference, 2.8% [95% CI, -2.2% to 7.7%]; P = .25). New or increased receipt of vasopressors occurred in 20.6% of patients in the fluid bolus group compared with 17.6% of patients in the no fluid bolus group, a systolic blood pressure of less than 65 mm Hg occurred in 3.9% vs 4.2%, respectively, cardiac arrest occurred in 1.7% vs 1.5%, and death occurred in 0.7% vs 0.6%. Death prior to day 28 (censored at hospital discharge) occurred in 218 patients (40.5%) in the fluid bolus group compared with 223 patients (42.3%) in the no fluid bolus group (absolute difference, -1.8% [95% CI, -7.9% to 4.3%]; P = .55).
Among critically ill adults undergoing tracheal intubation, administration of an intravenous fluid bolus compared with no fluid bolus did not significantly decrease the incidence of cardiovascular collapse.
ClinicalTrials.gov Identifier: NCT03787732.
低血压在危重症成人进行气管插管时很常见,并且会增加心脏骤停和死亡的风险。在接受气管插管的危重症成人中给予静脉输液是否能预防严重低血压、心脏骤停或死亡仍然不确定。
确定输液对严重低血压、心脏骤停和死亡发生率的影响。
设计、地点和参与者:这项随机临床试验纳入了美国 11 个重症监护病房的 1067 名接受镇静和正压通气下气管插管的危重症成人,于 2019 年 2 月 1 日至 2021 年 5 月 24 日期间入组。最后随访日期为 2021 年 6 月 21 日。
患者被随机分配接受 500 毫升静脉输液(n=538)或不接受输液(n=527)。
主要结局是心血管崩溃(定义为麻醉诱导后至气管插管后 2 分钟之间新接受或增加血管加压药治疗或收缩压<65mmHg,或麻醉诱导后至气管插管后 1 小时内发生心脏骤停或死亡)。次要结局是在第 28 天之前死亡的发生率,在出院时进行了删失。
在 1067 名随机患者中,有 1065 名(99.8%)完成了试验并纳入主要分析(中位年龄 62 岁[IQR,51-70 岁];42.1%为女性)。在输液组中,有 113 名(21.0%)患者发生心血管崩溃,在未输液组中,有 96 名(18.2%)患者发生心血管崩溃(绝对差异 2.8%[95%CI,-2.2%至 7.7%];P=0.25)。输液组中 20.6%的患者需要新接受或增加血管加压药治疗,而未输液组中为 17.6%,收缩压<65mmHg的患者分别为 3.9%和 4.2%,心脏骤停分别为 1.7%和 1.5%,死亡分别为 0.7%和 0.6%。在输液组中,有 218 名(40.5%)患者在第 28 天之前(以出院时删失)死亡,而在未输液组中,有 223 名(42.3%)患者死亡(绝对差异-1.8%[95%CI,-7.9%至 4.3%];P=0.55)。
在接受气管插管的危重症成人中,与不输液相比,给予静脉输液并不能显著降低心血管崩溃的发生率。
ClinicalTrials.gov 标识符:NCT03787732。